BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation

BioMarin Pharmaceutical has reached a significant regulatory milestone with the FDA's acceptance of a supplemental New Drug Application for its rare disease therapy, VOXZOGO. The agency has set a target action date for February 28, 2027, as the company seeks to expand the clinical utility and market reach of its key growth driver. This development is a pivotal moment for the pharmaceutical sector, as it underscores the commercial potential of specialized genetic treatments amid a period of stock price recovery for the company.

BioMarin Pharmaceutical recently announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for VOXZOGO, with a target decision date set for February 28, 2027. While the company's stock has shown signs of recovery with a 90-day return of 6.72%, it currently trades at approximately $59.20, which is a steep discount compared to the analyst-estimated fair value of $87.85. This regulatory progress follows a difficult period for the rare disease specialist, during which its three-year total shareholder return declined by 31.69%.

The company’s financial outlook is heavily reliant on the continued global expansion of its existing portfolio, particularly VOXZOGO and VIMIZIM. Revenue growth is being fueled by new patient starts and improved rare disease diagnosis rates globally. Beyond its current commercial products, BioMarin is advancing a robust pipeline of late-stage programs, including BMN 333 for achondroplasia and BMN 401 for ENPP1 deficiency, alongside label expansions for PALYNZIQ. These programs are designed to capitalize on growing patient pools identified through earlier and more accurate genetic testing, which could significantly expand the company's future addressable markets.

However, BioMarin faces several strategic risks that could impact its long-term valuation and market position. The company must navigate potential competition for VOXZOGO while managing high research and development (R&D) and SG&A spending that threatens to squeeze future profit margins. Additionally, while analysts see the stock as undervalued, its current price-to-earnings (P/E) ratio of 42.6x sits well above the U.S. biotech industry average of 17.4x. This suggests that the market has already priced in significant growth expectations, leaving the company vulnerable to valuation risks if its pipeline conversion or earnings trajectory fails to meet investor expectations.